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Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative
monogenetic disorder affecting carriers of premutation (PM) forms of the FMR1 gene,
resulting in a progressive development of tremors, ataxia, and neuropsychological
problems. This highly disabling disease is quite common in the general population with
an estimation of about 20 million PM carriers worldwide. The chances of developing
FXTAS increase dramatically with age, with about 45% of male carriers over the age
of 50 being affected. Both the gene and pathogenic trigger, a mutant expansion
of CGG RNA, causing FXTAS are known. This makes it an interesting disease to
develop targeted therapeutic interventions for. Yet, no such interventions are available
at this moment. Here we discuss in silico, in vitro, and in vivo approaches and how
they have been used to identify the molecular determinants of FXTAS pathology.
These approaches have yielded substantial information about FXTAS pathology and,
consequently, many markers have emerged to play a key role in understanding the
disease mechanism. Integration of the different approaches is expected to provide
crucial information about the value of these markers as either therapeutic target or
biomarker, essential to monitor therapeutic interventions in the future.
Keywords: RNA, Fragile X associated tremor ataxia syndrome (FXTAS), mouse model, computational modeling,
protein network
INTRODUCTION
Fragile X-associated Tremor and Ataxia syndrome (FXTAS) is a late onset neurodegenerative
disease that affects Fragile X premutation (PM) carriers. The Fragile X gene (FMR1) responsible for
the disease finds its origin on the X chromosome and codes for the Fragile X Mental Retardation
Protein called FMRP. This protein is essential in the neuronal development and synaptic plasticity
of the brain. The 5′ untranslated region (UTR) of the FMR1 gene carries a variable number of CGG
repeats, which is between 4 and 55 in healthy individuals. Due to the instability of the repeat the
CGG sequence can expand to 55–200 repeats over generations (Leehey, 2009; Berman et al., 2014;
Foote et al., 2016; Glineburg et al., 2018). These individuals are referred to as PM carriers.
FXTAS is characterized by several clinical features such as intention tremors and cerebellar gait
ataxia, which are proposed to be major clinical diagnostic criteria for FXTAS disease pathology.
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Other, more minor clinical criteria are Parkinsonism, working
memory deficit and executive function deficit (Berry-Kravis
et al., 2007; Leehey, 2009; Berman et al., 2014). Furthermore
the neurodegeneration is characterized by brain atrophy,
neuropsychiatric features and cognitive impairments or dementia
(Foote et al., 2016). It is estimated that in the general population
1:110-250 females and 1:260-800 males are PM carriers with an
interesting side note that not all carriers develop FXTAS due to
incomplete penetrance (Tassone et al., 2012; Hunter et al., 2014;
Foote et al., 2016; Glineburg et al., 2018). FXTAS penetrance
is about 40% in male carriers and only 11–18% in female
carriers (Berry-Kravis et al., 2007; Foote et al., 2016; Glineburg
et al., 2018). A major hallmark of the disease is the presence of
ubiquitin-positive intranuclear inclusions throughout the brains
of FXTAS patients (Figure 1).
To date there is no cure available for PM carriers or
FXTAS patients which is why development and validation of
relevant models is necessary (Leehey, 2009). This will allow
us to better understand this complex neurological disorder
and also to be used for drug development in the future. At
present, the onset and development of FXTAS is explained
by two main mechanisms (Botta-Orfila et al., 2016): (i) RNA-
mediated sequestration, and subsequent inactivation, of proteins
attracted by the CGG trinucleotide repeats in the 5′ UTR
region of FMR1 RNA and (ii) toxic aggregation of Repeat-
Associated Non-AUG (RAN) polyglycine peptides translated
from the FMR1 5′ UTR (FMRpolyG; Figure 1). Previous
work indicates that FMR1 RNA forms aggregates containing
specific proteins such as HNRNP A2/B1, MBNL1, LMNA,
and INA (Iwahashi et al., 2006). Also the FMRpolyG peptide
(Sellier et al., 2017) was found in the aggregates, together with
CUGBP1, KHDRBS1, and DGCR8 being involved in splicing
regulation, mRNA transport and regulation of microRNAs
(Sellier et al., 2010).
Here we discuss in silico, in vitro, and in vivo approaches
and how they have been used to identify the molecular
determinants of FXTAS pathology. Our aim is to provide
a comprehensive review for future research in the area.
We believe that synergetic approaches from different
research areas are necessary for FXTAS, because its
pathological substrate is still under debate and there is still
insufficient knowledge of targets for the development of a
therapeutic intervention.
IN SILICO APPROACHES TO PREDICT
MOLECULAR INTERACTIONS
OCCURRING IN FXTAS
Difficulties in the biochemical purification of protein–RNA
assemblies, which are extremely labile, make it extremely hard to
extract the aggregates and identify the molecules that are crucial
in disease spreading (Tartaglia, 2016). The use of computational
methods aids in characterizing RNA-binding proteins (RBPs)
with CGG repeats. We refer the reader to advanced reviews
for more details related to some sophisticated algorithms
(Cirillo et al., 2014).
PREDICTIONS OF PROTEIN–RNA
INTERACTIONS OCCURRING IN FXTAS
The ability of the first FMR1 exon (containing 79 CGG
repeats in the PM range) to interact with specific RBPs. was
assessed through the catRAPID algorithm (Agostini et al., 2013).
catRAPID estimates the binding potential through van der Waals,
hydrogen bonding and secondary structure propensities of both
protein and RNA sequences allowing identification of binding
partners (Bellucci et al., 2011). The library employed in the
study was composed of 3340 DNA-binding, RNA-binding, and
structurally disordered proteins (Livi et al., 2016).
catRAPID (Figure 2) identified known CGG-binding proteins
such as ROA (1, 2, and 3), SRSF (1, 4, 5, 6, 7, and 10), HNRNP
(C, D, M) as well as MBNL1 and KHDRBS3 (Cid-Samper et al.,
2018) (see section “In vitro Approaches to Predict Molecular
Interactions Occurring in FXTAS”). In addition, strong binding
propensities were found for an additional set of 92 proteins
that are known to aggregate in stress granules (Jain et al., 2016)
and a group of 37 RBPs that have strong potential to aggregate,
as predicted by the catGRANULE algorithm (Bolognesi et al.,
2016). Among the RBPs identified, there are 25 splicing factors,
including LSM3, SFPQ and TRA2A, 24 RBPs involved in RNA
metabolism, including FUS, RBM8A, AGO2 and stress granules
RBPs such as TIA1, MBNL1, and DDX1 (Cid-Samper et al., 2018)
as well as CIRBP and PTBP2 (Cirillo et al., 2013).
IN VITRO APPROACHES TO PREDICT
MOLECULAR INTERACTIONS
OCCURRING IN FXTAS
Protein interaction with CGG repeats can be determined
by several experimental in vitro approaches. The success
in discovering new findings is influenced by the technical
capacity to preserve the natural characteristics of the protein–
RNA partners, such as the secondary and tertiary structure,
electrostatic and hydrophobic interactions, hydrogen bonding,
rate of transcription of RNA and translation of protein, etc. We
refer the reader to advanced reviews for details related to the
experimental methods (Dasti et al., 2019).
CGG repeats form hairpins in vitro (Krzyzosiak et al., 2012).
UV-monitored structure melting indicates that they are more
stable than hairpins formed by CAG, CUG, or CCG repeats.
Although the in vivo structure might differ, due to interactions
with proteins and other molecules, crystallography supports
the model that CGG repeats have intermolecular duplexes
(Kiliszek et al., 2011).
RNA PULL-DOWN TO DETECT CGG
REPEATS INTERACTIONS
The RNA pull-down consists on a selective extraction of a
protein–RNA complex from a whole sample lysate, by using high-
affinity tags, e.g., biotin on the RNA molecule. After tagging the
known interaction partner, RNA, the RBPs complexed with it are
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FIGURE 1 | Proposed mechanisms of CGG-repeat toxicity in PM carriers. (A) Protein sequestration model: RNA binding proteins are sequestered through their
interactions with the expanded CGG-repeat FMR1 mRNA. These proteins can in turn recruit other proteins. The net result of the sequestration of these proteins is
that they are unavailable to carry out their normal functions and critical cellular processes are thereby altered or blocked. (B) Toxic polypeptide model: the ribosome
translation initiation complex stalls near the CGG repeat hairpin formed on the FMR1 mRNA. This promotes the repeat-associated non-AUG (RAN) translation of
FMR1 mRNA using a near-AUG start site. This results in a frame shift and the production of the polyglycine-containing polypeptide (FMRpolyG) that somehow
interfere with normal cell function or may be directly toxic.
purified by using agarose or magnetic beads. To identify which
proteins are associated with expanded CGG repeats, Sellier and
colleagues adopted an in vitro approach. Proteins extracted from
mouse brain and COS7 cell nuclei were captured on streptavidin
resin coupled to biotinylated in vitro-transcribed RNA composed
of 60CGG repeats, eluted, separated on SDS–PAGE gels and
identified by MALDI-TOF analysis. More than 20 proteins were
identified, including a heat-shock protein and several RBPs, such
as SRSF (1, 4, 5, 6, 7, and 10), MBNL1 and HNRNP-G (Sellier
et al., 2010). The list of interactors (Figure 2) included SPNR,
HNRNP-A1, HNRNP-A2/B, HNRNP-C, HNRNP-D, HNRNP-E,
and HNRNP-H (Sellier et al., 2010).
PROTEIN MICROARRAYS TO DETECT
FMR1 INTERACTIONS
Protein microarray technology was used to detect RBP
interactions with the first FMR1 exon (Cid-Samper et al.,
2018). In this approach, individual human proteins, expressed
in a eukaryotic system and subsequently purified, are isolated
in separated nitrocellulose chambers and the RNA labeled with
Cy5 is used for probing (Marchese et al., 2017). Both expanded
(79CGG, permutated range) and normal (21CGG) repeats were
probed on independent replicas and the 3′ UTR of a similar
length transcript, SNCA, was used as a control for the specificity
of RBP interactions (Marchese et al., 2017).
Using fluorescence intensities to measure binding affinities
(Cirillo et al., 2016), previously identified partners SRSF 1, 5,
and 6 ranked in the top 1% of all interactions, followed by
KHDRBS3 (2%) and MBNL1 (5%). The overall list included 85
RBPs showing an enrichment in Gene Ontology terms related to
splicing activity, as reported by cleverGO (Klus et al., 2015) and
includes several SRSF proteins, PCBP 1 and 2, HNRNP-A0 and F,
NOVA1, PPIG, and TRA2A (Figure 2).
RNA ELECTROPHORETIC MOBILITY
SHIFT ASSAY (RNA-EMSA) TO VALIDATE
INDIVIDUAL PROTEIN INTERACTIONS
WITH CGG REPEATS
In the RNA-EMSA assay protein–RNA interactions are detected
as migration differences in gel electrophoresis: the RNA probe
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FIGURE 2 | In silico and in vitro methods to identify protein interactors of expanded CGG repeats in the FMR1 mRNA. (A) The catRAPID approach can be used to
predict the protein partners of expanded CGG repeats exploiting calculations of secondary structure and a phenomenological potential for van der Waals and
hydrogen-bonding interactions; (B) RNA pull-down followed by mass-spectrometry reveals the most abundant protein interactors of FMR1 5′ UTR. (C) The protein
microarray approach allows to probe labeled FMR1 5′ UTR against the entire human proteome, revealing targets that are poorly abundant in the cell.
is labeled by radioactivity of by fluorescent or chemiluminiscent
dyes, and incubated with the whole protein extract from cell
lysate, in different concentrations of the first one. In case
the RNA is selectively bound to proteins, the electrophoretic
band will differ from a negative control, as a migration
shift. In this assay, an experimental secondary approach is
performed, by assessing competitive binding: an excess of
unlabeled RNA is incubated with the binding reaction and in case
the shifted signal decreases, there is evidence for specificity of
the binding.
Using RNA-EMSA, the binding of HNRNP-A2 to 105CGG
repeats was studied in the presence of the brain cytoplasmic
(BC1) RNA involved in neuronal translational (Muslimov et al.,
2011). Differently from 105CCC repeats, the 105CGG repeats
competed with binding of BC1 RNA to HNRNP-A2, which
indicates impairment of neuronal function. Using 105CGG
repeats at levels comparable to FMR1 abundance in PM disease
cells, the authors showed that distal dendritic delivery of BC1
RNA is significantly reduced while 105CCC repeats had no effect
on dendritic BC1 targeting (Muslimov et al., 2011).
RNase H PROTECTION APPROACH TO
CHARACTERIZE THE FMR1 R-LOOP
The RNase H protection approach is used to detect DNA and
RNA fragments in cell lysates. RNase H cleaves the target RNA
molecule at a specific site hybridized with a DNA probe. In these
specific sites, if a protein is bound, the hybridization is blocked,
therefore no cleavage by RNase H will occur.
It has been observed that transcription through the GC-rich
FMR1 5′ UTR region favors formation of a three-stranded nucleic
acid structure, composed of a DNA:RNA called R-loop formation,
with the nascent RNA assembling with the template DNA strand
(Loomis et al., 2014). Using DNA:RNA immunoprecipitation
of genomic DNA from cultured human dermal fibroblasts with
both normal and PM alleles, the authors reported for FMR1
R-loop formation As expected for R-loop formation. Treatment
with purified recombinant human RNases H1 and H2 eliminated
DNA–RNA interaction (Loomis et al., 2014).
FLUORESCENT IN SITU HYBRIDIZATION
CO-LOCALIZATION (FISH) TO LOCALIZE
CGG REPEATS IN THE CELL
Fluorescent in situ hybridization (FISH) co-localization
techniques require knowing in advance which RNA and protein
interaction will be studied. This technique is commonly used
in FXTAS research as it allows verifying where CGG repeats
localize with other molecules. By means of FISH coupled to
immunofluorescence it has been shown that CGG expansions
and TRA2A significantly co-localize in COS7 cells (Cid-Samper
et al., 2018). Similarly, co-localization of MBNL1, KHDRBS1
and HNRNP-G within CGG aggregates was observed in COS7
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cells (Sellier et al., 2010). By contrast, other in vitro identified
candidates such as SPNR, HNRNP-A1, HNRNP-A2/B, HNRNP-
C, HNRNP-D, HNRNP-E, and HNRNP-H have been shown by
FISH to have poor co-localization with CGG repeats (Sellier
et al., 2010). Several proteins, including a number of heat-shock
proteins, HNRNP-A2/B1, CUGBP1, lamin-A/C and MBP were
found to localize with ubiquitin-positive inclusions in CGG-
expressing Drosophila, KI mouse model and FXTAS patients.
Some of the co-localizations are model dependent. Indeed, it
should be noted that PURα co-localizes with cytoplasmic CGG
repeats in flies (Jin et al., 2007) but not in mammalian cells,
where it is found strictly nuclear (Sellier et al., 2010). So, given
the propensity of PUR-α to interact with CGG repeats (Cirillo
et al., 2013), it is possible that its subcellular localization prevents
physical interaction with RNA.
IN VIVO APPROACHES TO PREDICT
MOLECULAR INTERACTIONS
OCCURRING IN FXTAS
The development of animal models has provided the field with
important clinical but also molecular information regarding the
pathology associated with CGG repeat expansions on FMR1
Fragile X syndrome (FXS), PM carriers and FXTAS. PM carriers
of the expanded CGG repeat have a 2 to 8-fold elevation of
FMR1 mRNA levels when compared to healthy CGG repeat
individuals (Hagerman and Hagerman, 2002). Increased levels of
FMR1 mRNA with a CGG expansion are proposed to be toxic due
to sequestration of specific RNA binding proteins that are crucial
for normal cell function, partly resulting in FXTAS pathology.
This theory is supported by inclusions isolated from FXTAS
post-mortem brain tissue containing over 30 critical proteins,
such as Lamin A/C, KHDRBS1, Drosha, and HNRNP-A2
(Glineburg et al., 2018). The most prominent neuropathological
hallmark of FXTAS is the presence of eosinophilic, ubiquitin-
positive intranuclear inclusions in neurons and astroglia in
the entire brain upon post-mortem histological analysis (Greco
et al., 2002, 2006, 2007, 2008; Gokden et al., 2009). Additional
neuropathological features found in FXTAS are reduced number
of Purkinje cells, Bergmann gliosis, axonal swelling in the
granular cell layer of the cerebellum, and prominent cortical
and subcortical white matter pathology (Greco et al., 2002,
2006). A second mechanism more recently found suggests an
additional model for toxicity in FXTAS called repeat-associated
non-AUG (RAN) translation. This mechanism proposes that the
expanded CGG repeat is translated in absence of a canonical
start codon resulting in pathogenicity through translation of
a toxic polyglycine (FMRpolyG) peptide (Berman et al., 2014;
Glineburg et al., 2018). Over the past 10 to 15 years many well-
characterized mouse models have shown that aforementioned
theories could indeed contribute to disease pathology. These
mouse models also allowed us to characterize FXTAS disease
pathogenesis and progression together with the underlying
neurobiological changes and to develop and test highly potential
targeted therapeutic interventions. This part of the review will
describe the current available mouse models for FXTAS with their
FIGURE 3 | Schematic drawings representing the genetic constructs
designed for the Dutch and NIH CGG KI PM mouse models. The Dutch
mouse model has an intact mouse promoter followed by a human genetic
sequence flanking the inserted CGG repeat expansion upstream of the mouse
Fmr1 gene. The NIH CGG KI mouse has an in vitro generated CGG repeat
tract inserted to replace the mouse CGG8 also keeping the mouse Fmr1 gene
and promoter intact. In both cases there is immunodetection of
ubiquitine-positive inclusions.
specific aspects, advantages and limitations, and what insights
they have provided over the past years into disease mechanism.
THE DUTCH MOUSE
The first mouse model generated to exhibit much of the pathology
seen in affected PM carriers and in FXTAS pathology at the
genetic level but as well as histopathological and molecular
level was the Dutch mouse (CGGdut KI) model. This mouse
model was developed in Rotterdam at the Erasmus MC in
the Netherlands. This model was generated by replacing the
endogenous murine Fmr1 8CGG repeat with a human 98CGG
repeat containing the human FMR1 flanking regions. The
Fmr1 mouse promoter was left unchanged. This was done
by homologous recombination in embryonic stem (ES) cells
(Bontekoe et al., 2001; Foote et al., 2016). Upon paternal and
maternal transmission the CGGdut KI mouse showed mild
instability of the CGG repeat with both short expansions and
contractions present (Bontekoe et al., 2001; Willemsen et al.,
2003; Brouwer et al., 2007). The CGGdut KI mice (Figure 3)
have been bred into a C57BL/6J and FVB background over
several generations to establish lines with expanded alleles greater
than 450CGGs (Bontekoe et al., 2001; Berman and Willemsen,
2009). Although repeat lengths of more than 450CGGs were
found, no increased methylation of the Fmr1 gene has been
reported. When examining these mice at the histopathological
level clear ubiquitin-positive intranuclear inclusions could be
shown similar to what is seen in FXTAS post-mortem patient
brain. As mentioned before FXTAS patients are characterized
with elevated FMR1 mRNA and slightly decreased FMRP
protein. Although FXTAS is considered to be a late-onset
neurodegenerative disorder, some phenotypes of the disease
in patients and in the CGGdut KI mouse could suggest that
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FXTAS might also have features of a neurodevelopmental
disorder. Developmental abnormalities during the PM stage such
as altered learning and memory may contribute to the late
manifestation of FXTAS. For example PM carriers have a smaller
hippocampus that correlates with impaired performance in
standardized tests of memory (Hagerman, 2013). Hippocampal
neurons with an abnormal dendritic morphology have been
observed in FXTAS neurons at a time of development when
nuclear inclusions are not detectable yet. When observing
hippocampal neurons from the CGGdut KI mouse researchers
found cortical migration to be affected in these mice and that
these neurons upon culturing display shorter dendrites and have
a reduced dendritic complexity (Hunsaker et al., 2009, 2012;
Chen et al., 2010; Cunningham et al., 2011; Berman et al., 2014).
Recently, the impact of elevated Fmr1 mRNA levels on the
morphology of dendrites and axons was studied more in depth
(Drozd et al., 2019). Indeed, these morphological phenotypes
are associated with increased levels of Fmr1 mRNA because
upon treatment with shRNAs specifically targeting the Fmr1
mRNA these phenotypes are rescued. In addition, proteomic
analysis in the CGGdut KI mouse showed that upon rescue
of FMR1 mRNA levels a large number of important RBPs
such as Tia1, HNRNPll, and ROAA could be normalized.
Other rescued proteins are Rab-GTPases, which are critical for
synaptic function in neurons in brain developmental disorders.
Also Aldh4a1/P5CDH and Samm50, which are involved in
mitochondrial dysfunction, were found to be deregulated in these
mice confirming previous hypotheses indicating the important
role of mitochondria in FXTAS pathology. All these proteins
provide possible future pharmacological targetable molecules for
early therapeutic intervention for FXTAS. More research focusing
on other aspects of neurodevelopment in FXTAS such as the
role of FMRP in the PM stage is necessary before one can
categorize FXTAS to also be a neurodevelopmental disorder.
All together, the CGGdut KI mouse model nicely recapitulates
the histopathology and molecular changes observed in patients
(Berman and Willemsen, 2009; Foote et al., 2016).
THE NIH MOUSE
The National Institutes of Health developed a second KI mouse
model (CGGnih KI) with a CGG repeat length between 118-
120CGGs by generating a CGG repeat flanked by SfiI sites and
then ligating this CGG repeat into the target construct with
exon 1 of the mouse Fmr1 gene in the correct orientation
minimalizing changes to the mouse regions flanking the CGG
repeat, the gene itself and the promoter (Entezam et al., 2007;
Hoffman et al., 2012; Foote et al., 2016). This resulted in these
mice having a translational TAA stop codon upstream of the
CGG repeat. This TAA stop codon is present in the endogenous
mouse Fmr1 gene but not in the human FMR1 gene. These mice,
similar to the CGGdut KI mouse show moderate intergenerational
expansions with elevated Fmr1 mRNA levels and decreased
FMRP levels at the molecular level without any methylation of the
Fmr1 gene. Importantly, histopathological analysis revealed less
ubiquitin-positive intranuclear inclusions being present in these
mice compared to the CGGdut KI mouse (Entezam et al., 2007;
Foote et al., 2016).
PURKINJE CELL SPECIFIC MOUSE
MODEL
A Purkinje cell specific mouse model was generated to provide
evidence that the expanded CGG repeat is necessary to cause
FXTAS pathology similar to human and distinguish these effects
seen from possible alterations in the Fmr1 gene. To do so
transgenic mice were generated expressing a CGG repeat in the
context of Fmr1 (L7-CGG90-Fmr1) or in context of the enhanced
green fluorescent protein (L7-CGG90-EGFP) specifically in
Purkinje neurons using the pcp2/L7 promoter in the cerebellum
(Hashem et al., 2009). With these two lines it would be possible
to determine whether ectopic expression of a 90CGG expanded
repeat would cause neurodegeneration in the cerebellum or
not. A significant Purkinje cell loss was observed in both
the L7-CGG90-Fmr1 and L7-CGG90-EGFP mice (Figure 4).
Ubiquitin-positive intranuclear inclusions being the hallmark
of FXTAS could be found in Purkinje cells of both the lines
with the expanded CGG repeat but not in the control mice
suggesting an essential role for the expanded CGG repeat and
RNA in inclusion formation. It is assumed that the proteasome
degradation pathway is involved in FXTAS disease progression
in humans since essential proteins involved in this pathway are
found in ubiquitin-positive inclusions (Willemsen et al., 2003).
Inclusions in the Purkinje cell specific mice contained as well
the 20S core complex of the proteasome, heat-shock protein
HSP40 and RAD23B protein, which is a known protein of the
ubiquitin-mediated proteasome degradation pathway. Behavioral
examination revealed that mice expressing the expanded CGG
mRNA in the Purkinje cells had an impaired motor performance
on the rotarod test. These neuropathological and behavioral
observations provide evidence that expression of the CGG repeat
mRNA is sufficient to cause Purkinje cell dysfunction and loss
of neurons similar to that reported in FXTAS patients (Greco
et al., 2002). Although there might be a connection between
intranuclear inclusion formation and in this case Purkinje cell
death, such a conclusion could only be made upon understanding
the role of other essential proteins present in these inclusions.
FMRpolyG AND CGG-RNA TRANSGENIC
MICE
To further elaborate on the two hypotheses regarding the
pathogenic mechanism in PM and FXTAS pathology based on
expression of mutant FMR1 mRNA bearing an expanded CGG
repeat a new mouse model was suggested. How FMR1 mRNA
containing expanded CGG repeats is pathogenic was still unclear.
To study this, the lab of Charlet Berguerand at the Institut de
Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) in
France created two transgenic mouse models (Figure 5). The
first model contains the full human 5′ UTR of FMR1 with
expanded 99CGG repeats that express both the CGG-RNA as
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FIGURE 4 | Schematic representation of L7-(CGG)90 and L7 constructs. The
transgenes were driven by Purkinje cells specific, L7 promoter. A human
genomic FMR1 DNA fragment containing 90CGG repeats was inserted
upstream of the Fmr1 or EGFP coding region between the transcriptional and
translational start sites. The Fmr1 containing transgenes have a FLAG epitope
engineered into the 5′ region of the gene. A BGH polyadenylation site was
inserted 3′ region of the transgenes.
FIGURE 5 | Ubiquitous expression of expanded CGG-RNA in inducible
transgenic mouse model. The Tet-On system was used to generate bigenic
mice expressing a expanded CGG repeat at the RNA level in all tissues.
Expression of rtTA is controlled by the hnRNP promoter on a transgene. Upon
DOX administration rtTA will be activated and can bind the Tet Responsive
Element (TRE) on another transgene, inducing expression of the nCGG repeat
at the RNA level and eGFP at the protein level.
well as the FMRpolyG protein. The second line referred to as
the mutant line also expresses 99CGG repeats, but without the
non-canonical ACG start-codon and the surrounding 5′ UTR
sequence region only expressing the CGG-RNA and no protein
(Sellier et al., 2017). Both transgenic mouse lines have a CAG
promoter inserted within the Rosa26 locus and expression is
controlled by a loxP-polyadeneylation cassette (Sellier et al.,
2017). Using a ubiquitously and embryonically expressed Cre
recombinase results in deletion of the loxP cassette, which leads
to high expression of transgene RNA throughout the brain, heart
and liver, with less expression in skeletal muscle and the kidneys.
Transgene RNA expression is the same in both transgenic mouse
lines. The full human FMR1 5′ UTR transgenic mice showed
upon histological analysis FMRpolyG protein nuclear aggregates
that co-localize with ubiquitin in the brain (Sellier et al., 2017).
The mutant FMR1 5′ UTR mice did not show these aggregates.
The occurrence of CGG RNA foci in the brain of these mice
(Figure 5) is slightly lower compared to other previously reported
mouse models (Sellier et al., 2010, 2017). FMRpolyG protein
also accumulated in other tissue than the brain, which is similar
to what our group reported regarding FMRpolyG aggregates
in non-CNS tissues in FXTAS patients (Buijsen et al., 2014).
Other sense proteins such as the polyalanine (FMRpolyA) and
polyarginine (FMRpolyR) peptides from other reading frames
were not observed in these mice. There is to some extent
neuronal cell death and little loss of Purkinje neurons in the mice
expressing CGG-RNA and the FMRpolyG protein but not in the
mice expressing only CGG-RNA (Sellier et al., 2017).
FMR1 OVEREXPRESSING MICE
FMR1 mRNA toxicity is mentioned several times before to
be one of the hypothesis causing FXTAS pathology and is
supported by elevated levels of FMR1 mRNA with an expanded
CGG repeat (Hagerman and Hagerman, 2002). It could be that
toxicity occurs due to expression of an expanded CGG repeat
or because of just elevated FMR1 mRNA levels independent
of the CGG repeat being present. A Drosophila model shows
that repeat length is a direct cause of pathology since longer
repeats show extreme retina pathology while short repeats result
in little pathology (Jin et al., 2003). To confirm these findings
in mice, transgenic mice were generated overexpressing FMR1
mRNA with a normal length CGG repeat consisting of 29CGGs
(Fernandez et al., 2012). Human FMR1 cDNA with 29CGG
repeats under control of a SV40/T7 promoter was injected in
oocytes to generate these transgenic 29CGG mice with 20–100
fold increase in FMR1 mRNA in tissues such as liver, cerebral
cortex and cerebellum. Although these mice express extreme
levels of FMR1 mRNA, there was no significant difference in
general activity or anxiety-related behaviors in open-field tests,
which suggests that expression of FMR1 mRNA alone is not
enough to induce pathology but that a CGG repeat expansion is
necessary for pathology to occur.
A yeast artificial chromosome (YAC) containing the full-
length human FMR1 gene was used to generate transgenic mice
overexpressing FMR1 mRNA to study the toxic effect of FMR1
mRNA as well as to study CGG repeat instability (Peier et al.,
2000; Peier and Nelson, 2002). These mice were generated by
direct microinjection of purified YAC DNA containing a 92CGG
repeat isolated from an adult male permutation carrier into
the pro-nuclei of fertilized FVB/N mouse oocytes and then
transferred into foster mice which eventually led to identifying
a mouse line having a repeat containing 90CGGs (Peier and
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Nelson, 2002). These YAC mice show a 2–3 fold increase in
expression of FMR1 mRNA and a 10–15 fold increase in FMRP
protein production (Peier et al., 2000; Spencer et al., 2008).
Importantly to mention is that histological analysis presented no
changes in overall brain morphology due to overexpression of
FMR1 mRNA or FMRP. When YAC mice were cross-bred with
Fmr1 KO mice lacking FMRP protein, some of the pathological
features attributed to the absence of FMRP could be reversed
and even overcorrected which also resulted in some abnormal
behaviors. The authors attributed phenotype to overexpression
of FMRP but the high levels of FMR1 mRNA could also have
contributed to these behavioral effects (Spencer et al., 2008).
INDUCIBLE MOUSE MODELS
As mentioned before it was not yet clear whether overexpression
of RNA bearing normal CGG repeat length or an expanded
CGG repeat is sufficient to induce toxicity in animal models
and how to translate results in mice to the PM and FXTAS
pathology. To further elaborate on this question two additional
doxycycline inducible transgenic mouse models were generated.
Both mouse models consisted of two transgenic mouse lines
differing in the promoter used. The main advantage of both
models is that expression of the transgene can be switched
on and off using doxycycline. The first mouse line expresses
the tetracycline response element (TRE) and the other line
expressing the reverse tetracycline-controlled transactivator
protein (rtTA), which can be activated using doxycycline or
doxycycline-derivative in drinking water or food. The TRE-
element was coupled to an expanded CGG repeat in frame
with eGFP while the rtTA was coupled to an hnRNP promoter.
Both mouse lines were crossbred generating double transgenic
offspring with ubiquitous expression of 90CGG repeat RNA
(hnRNP-rtTA/TRE-90CGG-eGFP; Figure 6). Strange enough
these mice died within 5 days after induction of the transgene
using doxycycline. After histopathological analysis of the
liver and molecular analysis two markers, cytochrome C
and glutathione oxidase (GPX1), could be identified being
affected in the livers with increased steatosis, mitochondrial
dysfunction and subsequent apoptosis. Due to the early death
of these mice no neuropathology could be observed. In
summary this mouse model taught us that in vivo expression
of expanded CGG RNA leads to severe toxicity in the
liver by affecting reactive-oxygen species (ROS) signaling
(Hukema et al., 2014).
Since FXTAS pathology is considered to be a
neurodegenerative disease, it was clear that the next step
would be to generate a brain specific doxycycline inducible
mouse model expressing RNA containing an expanded CGG
repeat. For this a brain specific prion protein (PrP)-rtTA
driver was used to activate expression of normal length CGG
RNA or expanded CGG repeat RNA fused to eGFP (Hukema
et al., 2015; Castro et al., 2017). The PrP promoter drives
expression in glial cells and neurons in the central nervous
system (CNS). Compared to the hnRNP-rtTA mouse line,
these mice could be treated for several weeks with doxycycline
without any apparent liver toxicity. The RNA bearing an
expanded CGG repeat was expressed the strongest in the
cerebellum, hippocampus and striatum. Examining brain
sections under the microscope showed ubiquitin-positive
intranuclear inclusions co-localizing with FMRpolyG-positive
intranuclear inclusions. Inclusion formation was followed
in time showing increasing numbers and size when mice
were longer treated with doxycycline. Other FXTAS-related
proteins such as 20S core complex of the proteasome, HSP40
and RAD23B could also be found co-localizing with the
ubiquitin-positive aggregates. Our group could show that
FIGURE 6 | Schemes of the mouse transgene constructs. Expression of FMRpolyG is pathogentic in mice and the immunohistochemistry for FMRpolyG N-terminus
of cerebellum and hippocampus areas of 6-month-old bigenic CMV-cre/full-length or mutant FMR1 5′-UTR transgenic mice shows occurrence of inclusions.
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FIGURE 7 | Diagram of DNA fragment used for pronuclear injection with either
an 11CGG or 99CGG trinucleotide repeat expansion on exon.
Astroglial-specific expression of nCGG repeat RNA yields RAN translation and
formation of ubiquitin-positive and FMRpolyG-positive inclusions in astroglia
and neurons.
introducing a wash-out period at an early stage was enough to
halt and even reverse inclusion body formation. When repeating
the wash-out step at a later point in time disease pathology
could only be halted but not reversed (Hukema et al., 2015;
Castro et al., 2017). Upon doxycycline induction the brain
specific inducible mice had deficits in the compensatory eye
movements. By turning off expression of the RNA with an
expanded repeat this functional phenotype could be stopped
(Hukema et al., 2015). After doxycycline induction double
transgenic brain specific inducible mice performed poorly on
the rotarod test indicating that motor performance is affected,
more specifically motor coordination and motor learning which
was also in line with the high number of intranuclear inclusions
observed in lobule X of the cerebellum. When examined in
the open-field test for emotional disturbance these mice were
more anxious but had no deficits in emotional learning nor
memory impairments correlating with intranuclear inclusions
found in the amygdala and the hippocampus (Hukema et al.,
2015). Behavioral phenotype and rescue were paralleled by
the intranuclear inclusions formed in several brain regions
such as lobule X of the cerebellum, the central amygdala and
basolateral nuclei region of the amygdala, and hippocampal
sub-regions such as the dentate gyrus and third cornu ammonis
region of the hippocampus (Castro et al., 2017). Turning off
transgene expression could halt functional phenotype and
even reverse neuropathology if intervened at an early stage
potentially suggesting that brain region specific therapeutic
intervention might be beneficial for FXTAS patients in the future
(Castro et al., 2017).
ASTROCYTE-SPECIFIC MOUSE MODEL
The FXTAS field has been provided with many interesting
mouse models but there are still questions left unanswered.
One interesting question in the field concerns the specific
role of astrocytes in FXTAS pathology. What is the role of
astroglial cells in FXTAS? Is for example expression of an
expanded CGG repeat enough to induce pathology? FXTAS
patient brains have inclusions throughout the entire brain,
in neurons but also in astroglial cells such as the Bergmann
glia in the cerebellum (Willemsen et al., 2003). Although the
CGGdut KI mouse model of FXTAS recapitulates most aspects
seen in FXTAS, these mice have relatively few numbers of
astrocytes with intranuclear inclusions. Therefore an astroglial-
specific mouse model was necessary. This transgenic mouse line
with a C57BL/6j background was generated through pronuclear
injection using a astrocyte-specific Gfa2 promoter to induce
expression of an expanded 99CGG repeat fused to an eGFP
marker gene only in astrocytes (Figure 7) (Wenzel et al., 2019).
Immunocytochemical analysis of eGFP expression patterns show
expression of 99CGG RNA was restricted to astroglia and
Bergmann glia only and was not present in neurons, microglia
or oligodendrocytes. Ubiquitin-positive and FMRpolyG-positive
inclusions were observed in the nucleus of astroglia with
inclusion bodies also being present in the cytoplasm of astrocyte
processes. Although astrocytes with inclusion bodies were low in
number, they were widely distributed in the brain such as in the
neocortex, cerebellum and occasionally in subcortical regions in
the hypothalamus and some brain stem nuclei. These mice had
no sign of Purkinje neuronal dropout as well as no ubiquitin-
positive inclusions in Purkinje cells could be found (Sellier et al.,
2017; Wenzel et al., 2019). This study was the first of its kind
to provide evidence of FXTAS related RAN-translation products
being present in mouse astroglia. Surprisingly, these mice also
had ubiquitin-positive intranuclear inclusions in neurons even
though there was no leaky expression in neurons of the Gfa2-
promoter and these cells did not express the expanded 99CGG
RNA suggesting a prion-like spread of pathology, similar to what
is seen in other models, from astrocytes to neurons by a cell-
to-cell transfer mechanism (Westergard et al., 2016). Several
behavioral tests were performed to examine neurological disease
phenotypes associated with FXTAS pathology. These mice had
difficulty with basic gait parameters such as stance time and
range of motion. Also when placed on the ladder rung test
their motor performance was clearly affected. These mice did
not suffer from any emotional disturbance nor memory learning
deficits. Although this model presents evidence of key hallmarks
of FXTAS pathology, more work is necessary to further elaborate
on the role of astroglia in FXTAS disease pathology.
CONCLUSION
Different experiments have been done to study the expanded
CGG repeats in the FMR1 gene. Despite many insights, the
different in silico, in vitro, and in vivo approaches have
not yet resulted in a targeted therapeutic intervention for
FXTAS. Indeed, while we know the exact mutation leading to
disease, we still could not identify the pathogenic trigger, or
combination of triggers.
The fact that a number of proteins have been consistently
found with different approaches is reassuring that the synergy
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from different research areas give hints on their roles in
pathology. For instance, studies based on RNA-pulldown (Sellier
et al., 2010) and protein-microarray approaches (Cid-Samper
et al., 2018) consistently show that CGG triplets, which are
known to form stable hairpins in vitro (Krzyzosiak et al., 2012),
interact physically with proteins (e.g., HNRNPs and SRSFs)
that have domains annotated as preferably binding single-
stranded regions (e.g., RRM domains). These results, supported
by catRAPID predictions (Cirillo et al., 2013), not only indicate
that a number of interactions could occur in loop regions of
the RNA but also suggest that the structural disorder, which
is found enriched by catGRANULE (Bolognesi et al., 2016)
in protein partners such as TRA2A (Cid-Samper et al., 2018),
might be involved in the binding, in addition to canonical
domains (Castello et al., 2016). Thus, loop regions of the
RNA or disordered regions of proteins could be the target for
therapeutic intervention.
Candidates identified in in silico and in vitro approaches
can serve as targets for intervention or as biomarkers to test
the therapy can be determined by performing in vivo studies.
For instance, the 9-hydroxy-5,11-dimethyl-2-(2-(pi-peridin-
1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium (also named 1a)
compound has been prioritized as a candidate for its ability
to bind to loops produced by unpaired G-G nucleotides in
CGG hairpins (Disney et al., 2012). The 1a compound has
been used in cellular models to prevent interactions with RBPs
such as TRA2A and consequent co-aggregation (Cid-Samper
et al., 2018). In agreement with this finding, it has been
reported that 1a and structurally similar compounds reduce
RAN translation of FMR1 in cultured cells and patient-derived
neurons (Su et al., 2014). Three small-molecule RAN inhibitors
have been recently shown to interact with CGG and GGGGCC
repeat RNAs by circular dichroism and native gel analysis:
BIX01294, CP-31398, and propidium iodide (Green et al., 2019).
These small, bioactive compounds can selectively inhibit RAN
translation across multiple disease-causing repeat expansion
mutations and could therefore be employed in future treatments
(Green et al., 2019).
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